Targeted tumor therapy with the TGF-beta2 antisense compound AP 12009

DOI zum Zitieren dieses Dokuments:: 10.5283/epub.805

Schlingensiepen, Karl-Hermann ; Schlingensiepen, Reimar ; Steinbrecher, Andreas ; Hau, Peter ; Bogdahn, Ulrich ; Fischer-Blass, Birgit ; Jachimczak, Piotr

PDF
(903kB) - Nur für Mitarbeiter des Archivs

Veröffentlichungsdatum dieses Volltextes: 05 Aug 2009 13:24

Alternative Links zum Volltext:DOI Pubmed Verlag

Details

Bibliographische Daten exportieren

Zusammenfassung

TGF-beta overexpression is a hallmark of various malignant tumors. This is due to the pivotal role of TGF-beta as it regulates key mechanisms of tumor development, namely immunosuppression, metastasis, angiogenesis, and proliferation. We have developed a new immunotherapeutic approach for the treatment of malignant tumors based on the specific inhibition of TGF-beta2 by the antisense ...